Drug Profile
Research programme: amino acid transporter inhibitors - Quadriga BioSciences
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Quadriga BioSciences
- Class Antineoplastics
- Mechanism of Action Amino acid transport system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 10 Oct 2017 Quadriga BioSciences receives SBIR grant from National Institutes of Health for amino acid transporter inhibitor development in Glioblastoma multiforme
- 19 Jul 2016 Preclinical trials in Solid tumours in USA (unspecified route)